aminolevulinic acid (ala) as a prodrug in photodynamic therapy of cancer
Clicks: 175
ID: 157953
2011
Article Quality & Performance Metrics
Overall Quality
Improving Quality
0.0
/100
Combines engagement data with AI-assessed academic quality
Reader Engagement
Steady Performance
30.0
/100
174 views
21 readers
Trending
AI Quality Assessment
Not analyzed
Abstract
Aminolevulinic acid (ALA) is an endogenous metabolite normally formed in the mitochondria from succinyl-CoA and glycine. Conjugation of eight ALA molecules yields protoporphyrin IX (PpIX) and finally leads to formation of heme. Conversion of PpIX to its downstream substrates requires the activity of a rate-limiting enzyme ferrochelatase. When ALA is administered externally the abundantly produced PpIX cannot be quickly converted to its final product - heme by ferrochelatase and therefore accumulates within cells. Since PpIX is a potent photosensitizer this metabolic pathway can be exploited in photodynamic therapy (PDT). This is an already approved therapeutic strategy making ALA one of the most successful prodrugs used in cancer treatment.
| Reference Key |
golab2011moleculesaminolevulinic
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | ;Jakub Golab;Kamil Bojarczuk;Małgorzata Wańczyk;Magdalena Winiarska;Magdalena Gabrysiak;Małgorzata Firczuk;Angelika Muchowicz;Małgorzata Wachowska |
| Journal | Journal of ethnopharmacology |
| Year | 2011 |
| DOI |
10.3390/molecules16054140
|
| URL | |
| Keywords |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.